Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2000 2
2001 1
2002 2
2003 3
2004 3
2005 8
2006 4
2007 5
2008 12
2009 14
2010 8
2011 10
2012 10
2013 11
2014 15
2015 13
2016 2
2017 10
2018 15
2019 15
2020 20
2021 24
2022 26
2023 36
2024 20

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

242 results

Results by year

Filters applied: . Clear all
Page 1
Mucositis and Infection in Hematology Patients.
Blijlevens NMA, de Mooij CEM. Blijlevens NMA, et al. Int J Mol Sci. 2023 May 31;24(11):9592. doi: 10.3390/ijms24119592. Int J Mol Sci. 2023. PMID: 37298545 Free PMC article.
Biomarkers and non-invasive tests for gastrointestinal mucositis.
Kuiken NSS, Rings EHHM, Blijlevens NMA, Tissing WJE. Kuiken NSS, et al. Among authors: blijlevens nma. Support Care Cancer. 2017 Sep;25(9):2933-2941. doi: 10.1007/s00520-017-3752-2. Epub 2017 May 24. Support Care Cancer. 2017. PMID: 28536886 Free PMC article. Review.
Infections in patients with hematological cancer: recent developments.
O'Brien SN, Blijlevens NM, Mahfouz TH, Anaissie EJ. O'Brien SN, et al. Among authors: blijlevens nm. Hematology Am Soc Hematol Educ Program. 2003:438-72. doi: 10.1182/asheducation-2003.1.438. Hematology Am Soc Hematol Educ Program. 2003. PMID: 14633794 Review.
Engineering of CD34+ progenitor-derived natural killer cells with higher-affinity CD16a for enhanced antibody-dependent cellular cytotoxicity.
van Hauten PMM, Hooijmaijers L, Vidal-Manrique M, van der Waart AB, Hobo W, Wu J, Blijlevens NMA, Jansen JH, Walcheck B, Schaap NPM, de Jonge PKJD, Dolstra H. van Hauten PMM, et al. Among authors: blijlevens nma. Cytotherapy. 2024 Mar;26(3):252-260. doi: 10.1016/j.jcyt.2023.11.009. Epub 2023 Dec 19. Cytotherapy. 2024. PMID: 38127030 Free article.
Manufacturers' views on outcome-based agreements.
Barjestehvan Waalwijk van Doorn-Khosrovani S, Timmers L, Pisters-van Roy A, Gijzen J, Blijlevens NMA, Bloemendal H. Barjestehvan Waalwijk van Doorn-Khosrovani S, et al. Among authors: blijlevens nma. J Mark Access Health Policy. 2021 Oct 29;9(1):1993593. doi: 10.1080/20016689.2021.1993593. eCollection 2021. J Mark Access Health Policy. 2021. PMID: 34745459 Free PMC article.
Filling the gaps of patient information and comprehension.
Ector GICG, Hermens RPMG, Blijlevens NMA. Ector GICG, et al. Among authors: blijlevens nma. Curr Opin Oncol. 2020 Jul;32(4):262-268. doi: 10.1097/CCO.0000000000000633. Curr Opin Oncol. 2020. PMID: 32541311 Review.
Host impairments in patients with neoplastic diseases.
Donnelly JP, Blijlevens NM, van der Velden WJ. Donnelly JP, et al. Among authors: blijlevens nm. Cancer Treat Res. 2014;161:1-41. doi: 10.1007/978-3-319-04220-6_1. Cancer Treat Res. 2014. PMID: 24706220 Free PMC article. Review.
242 results